Trinity Biotech plc (TRIB)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 102 | 81 | 63 | 57 | 62 | 44 | 44 | 60 |
| Operating profit | $m | -11 | -11 | ||||||
| Net profit | $m | -6 | 1 | -41 | -24 | -32 | -37 | -37 | -20 |
| EPS reported | $ | -60.00 | -60.60 | ||||||
| Operating cashflow per share | $ | -9.58 | -10.08 | ||||||
| Capex per share | $ | 10.05 | 0.14 | ||||||
| FCF per share | $ | -19.63 | -10.22 | ||||||
| Free cash flow | $m | -12 | -6 | ||||||
| Net debt | $m | 122 | 133 | ||||||
| Book value equity | $m | -72 | -72 | ||||||
| Book value per share | $ | -116.3 | -115.9 | ||||||
| Number of shares | m | 0.62 | 0.62 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -0.20 | -0.20 | ||||||
| P/S LTM | x | 0.34 | 0.33 | ||||||
| P/FCF LTM | x | -1.21 | -2.32 | ||||||
| EV/EBITDA LTM | x | -6.90 | -17.23 | ||||||
| EV/Sales LTM | x | 3.37 | 9.12 | ||||||
| Earnings Yield LTM | % | -2.54% | -4.57% | ||||||
| FCF Yield | % | -82.70% | -43.18% | ||||||
| Quality | |||||||||
| ROE | % | +51.92% | +68.09% | ||||||
| ROIC | % | -15.27% | -15.05% | ||||||
| Operating margin | % | -26.07% | -25.66% | ||||||
| Gross margin | % | +38.57% | +35.40% | ||||||
| FCF/Sales | % | -27.75% | -14.46% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -28.87% | -28.74% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.09 | -0.05 | ||||||
| Net Debt/EBITDA | x | -6.21 | -15.51 | ||||||
| EBIT/Net interest | x | -0.87 | -0.53 | ||||||
| Net debt/market cap | % | +8.65% | +47.56% | ||||||
| Net debt/Equity | x | -1.69 | -1.85 | ||||||
| Gross debt/equity | x | -1.92 | -1.92 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Africa, Asia, and Europe, catering to both clinical laboratory and point-of-care diagnostic markets. Its extensive range of clinical laboratory offerings encompasses diagnostic tests and specialized instrumentation for identifying numerous infectious diseases. These include Lyme disease, sexually transmitted infections like syphilis and herpes, SARS-CoV-2, and a variety of viral pathogens such as Epstein Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, and varicella. Additionally, Trinity Biotech provides in-vitro diagnostic products centered on haemoglobin A1c for the crucial monitoring, diagnosis, and risk assessment of diabetes. The company's product development incorporates diverse assay formats, including immunofluorescence, enzyme-linked immunosorbent (ELISA), Western blot, and line immunoassays. It also supplies a suite of reagent products, including ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase, vital for diagnosing liver and kidney disorders, as well as haemolytic anaemia. Beyond diagnostics, Trinity Biotech serves the life sciences industry and research facilities by supplying raw materials. The company's customer base comprises public health authorities, non-governmental organizations, and both clinical and reference laboratories. Its products are distributed through a dedicated direct sales force, complemented by a broad network of independent distributors and strategic partnerships.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Africa, Asia, and Europe, catering to both clinical laboratory and point-of-care diagnostic markets. Its extensive range of clinical laboratory offerings encompasses diagnostic tests and specialized instrumentation for identifying numerous infectious diseases. These include Lyme disease, sexually transmitted infections like syphilis and herpes, SARS-CoV-2, and a variety of viral pathogens such as Epstein Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, and varicella. Additionally, Trinity Biotech provides in-vitro diagnostic products centered on haemoglobin A1c for the crucial monitoring, diagnosis, and risk assessment of diabetes. The company's product development incorporates diverse assay formats, including immunofluorescence, enzyme-linked immunosorbent (ELISA), Western blot, and line immunoassays. It also supplies a suite of reagent products, including ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase, vital for diagnosing liver and kidney disorders, as well as haemolytic anaemia. Beyond diagnostics, Trinity Biotech serves the life sciences industry and research facilities by supplying raw materials. The company's customer base comprises public health authorities, non-governmental organizations, and both clinical and reference laboratories. Its products are distributed through a dedicated direct sales force, complemented by a broad network of independent distributors and strategic partnerships.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free